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In view of an urgent need for novel therapeutics that
have a positive impact on morbidity and mortality of
chronic diseases, the field is now moving more quickly
towards clinical translation from biomarker identification
to the development of an companion diagostic (CDx)
test. The implimentation of such CDx test is driven by
smart preclinical validation, a better study design and
improved surrogate readouts using currently available
methodologies and diagnostic techniques. Moreover,
upcoming novel biomarkers and diagnostic technologies
will soon permit a more accurate and efficient assessment
of disease progression and regression. The ability of bio-
markers to improve treatment and reduce health-care
costs is potentially greater than in any other area of cur-
rent medical research. For example, the American Society
of Clinical Oncology estimates that routinely testing peo-
ple with colon cancer for mutations in the K-RAS onco-
gene would save at least US $600 million a year. On the
other side, many papers in the course of biomarker dis-
covery projects have been published yet, but only few
clinically useful biomarkers have been patented and suc-
cessful validated for routine clinical practice. The reasons
for the limitation to bring biomarkers successful on the
market are manifold. Regulatory and scientific hurdles as
well as lack in the biomarker validation and lack in
the technical validation have been cited as one of the
main reasons for the slow growth in this area. Whilst the
majority of the published biomarkers will not be trans-
lated into diagnostic tests, the growth of biomarker used
in clinical diagnostics indicates that the future of
the industry will lie in the CDx co-development. The first
drug introduced using the CDx co – development –
Herceptin (trastuzumab; Roche/Genentech) – has now
been on the market for several years. Our study focus on
some economics and technical factors that should be
considered to successfully develop and market a compa-
nion diagnostic test, based on lessons learned from
recent case studies. A proposed framework of considera-
tions to be addressed at the various stages of developing
effective companion diagnostic test is also presented.
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